WASHINGTON, D.C. (WVDN) – U.S. Senators Shelley Moore Capito (R-W.Va.) and Mark Warner (D-Va.), reintroduced the Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act, bipartisan legislation to encourage early assessment and diagnosis of Alzheimer’s. Companion legislation was also introduced in the U.S. House of Representatives by Linda Sanchez (D- Calif.), Darren LaHood (R-Ill.), Doris Matsui (D-Calif.), and Gus Bilirakis (R-Fla.).
“As we continue to search for breakthroughs in the fight against Alzheimer’s, we must ensure our health care system is doing its part to identify the disease earlier and connect patients and families with the tools they need. The CHANGE Act focuses on practical improvements—like earlier screening and detection—that can make a meaningful difference right now. I’m proud to reintroduce this bill to help improve outcomes, ease the burden on caregivers, and move us closer to ending this devastating disease,” Senator Capito said.
“Having watched my mother battle Alzheimer’s for a decade before her passing, I know this is a devastating disease that impacts not just the individual, but the entire family. Our legislation is key to helping secure an early diagnosis that will allow for better care, earlier access to treatment, and more support for families navigating this difficult journey,” Senator Warner said.
“Like countless families across the country, mine has personally felt the heartbreaking toll of Alzheimer’s,” Representative Sánchez said. “Having lost both of my parents to this cruel disease, I understand how critical early diagnosis can be. Our bipartisan, bicameral bill would early assessments and offer crucial resources for families. As our population continues to age and diagnoses expected to rise, we can’t afford to wait.”
“Alzheimer’s affects millions of Americans, and we must be relentless in our search for a cure,” Representative LaHood said. “I am proud to work alongside Rep. Sánchez to reintroduce the CHANGE Act to strengthen existing tools within Medicare, helping to streamline and broaden the ability for earlier diagnosis of dementia. It is critical that Congress find ways to support patients, their families, and caregivers.”
“We need a comprehensive approach to tackle the devastating impact of Alzheimer’s and to support the millions of Americans battling against this disease. Early detection and intervention are crucial to improve care and prolong the life of loved ones,” Representative Matsui said. “The CHANGE Act provides important tools to deliver early support and high-value care. I applaud my colleagues for advancing this bipartisan effort as we continue taking steps forward to prevent, treat, and put an end to Alzheimer’s.”
“As research continues to yield advancement in the development of more treatment options for patients with Alzheimer’s, we know that early detection, diagnosis and intervention offers the best promise for disease management,” Representative Bilirakis said. “My family has coped with the devastating impacts of this horrific disease for more than a decade, so I understand the toll it takes on the patient and his or her loved ones as it progresses. We owe it to our fellow Americans to develop a system of care that prioritizes education, screening and assessment so that patients can enjoy the best possible quality of life.”
The CHANGE Act is endorsed by: UsAgainstAlzheimer’s, American Academy of Neurology, Alzheimer’s Association, Alzheimer’s Foundation of America, AMDA – The Society for Post-Acute and Long-Term Care Medicine, Alliance for Aging Research, Partnership to Fight Chronic Disease, Gerontological Society of America, American Society of Consultant Pharmacists, Latinos Against Alzheimer’s, and USAging.
“The reintroduction of the CHANGE Act is a powerful display of bipartisan, bicameral leadership stepping up to confront the growing Alzheimer’s crisis. Senators Capito and Warner, along with Representatives Sánchez, LaHood, Matsui, and Bilirakis, recognize that early detection and timely intervention are extremely important to improving outcomes for patients and reducing strain on families and our healthcare system. UsAgainstAlzheimer’s proudly supports this legislation, which shifts our country’s approach from reacting too late to acting early—where we have the greatest chance to change lives and make a difference,” George Vradenburg, CEO and Founder of UsAgainstAlzheimer’s, said.
BACKGROUND:
Approximately 7.2 million Americans age 65 and older are living with Alzheimer’s disease in 2025. That number could grow to a projected 13.8 million by 2060. The direct financial costs of Alzheimer’s disease and related dementias will also continue to increase exponentially, with projections indicating they will reach just under $1 trillion by 2050.
The CHANGE Act would better utilize the existing Welcome to Medicare initial exam and Medicare annual wellness visits to screen, detect, and diagnose Alzheimer’s and related dementias in their earliest stages.
Now, as new treatments are approved and glimpses at what could be on the horizon for those living with the disease emerge, ensuring screening and diagnosis is taking place is more essential than ever. An early documented diagnosis communicated to the patient and caregiver enables early access to care planning services and available medical and non-medical treatments and optimizes patients’ ability to build a care team, participate in support services, and enroll in clinical trials. It also would allow this devastating disease to be caught in its earliest stages, and ensure appropriate access to treatment.
Legislative text is available here.
